MSB 1.34% $1.51 mesoblast limited

Revascor, page-24

  1. 12,359 Posts.
    lightbulb Created with Sketch. 1105
    I agree with below comment, this is MESO however there is alway good reason to look at others, that way we establish a control to compair.Today CSL releast top line results for MACE , Not good, Mr Market cut the market cap by $ 7 billion au. I would bet the market would have gone up 7 billion if it had been good results. That would mean a product for MACE at pre BLA stage has been valued by the market at around 14 billion. I do not think this is a unreasonable valuation given the size of the indication.Revascor has the data CSL wanted pluss a lot more. Clearly MSB nor the FDA have the track recored to support such a valuation however that could be reversed by a single positive from the FDA. The up side is huge . A market cap of US$ 20 to 30 billion on one approval is not over the top.And the down rampers can laugh ridicule and sink to name calling but its not going to change the outcome of approval.

    14 billion hey. Barry

    27c

    Aloha.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.